The demographic diversity of the U.S. is constantly rising, however, minorities including Asian Americans, Native Hawaiians, and Pacific Islanders (AANHPIs) are lacking. We are unable to achieve health equity without the knowledge that comes with having minorities involved in the clinical trial process. Diversity in these trials will enable the scientific community to provide more accurate information for those who are underrepresented but are using the medication or therapy. In this document we discuss ways in which policy makers, the industry, researchers, providers, the community, and advocates can improve clinical trial diversity.